ReviewTrends in biotechnology2026
Scientific and operational maturity of CE-MS: are we close?
Review in Trends in biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Capillary electrophoresis-mass spectrometry (CE-MS) has regained momentum through advances in sensitivity, separation efficiency, and expanding applications in proteomics, metabolomics, and biopharmaceutical analysis. These developments have led to increasing claims that CE-MS is approaching technological maturity. However, while scientific capability is well established, its operational maturity-defined by robustness, reproducibility, and ease of deployment-remains limited. Drawing lessons from the industrialization of liquid chromatography-mass spectrometry, we argue that widespread adoption depends not only on analytical performance but also on engineering architectures that stabilize interfaces and enable standardized workflows. Ultimately, the future of CE-MS will depend as much on system-level engineering as on advances in separation science.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.